Search results for "C70"

showing 10 items of 98 documents

Helmet continuous positive airway pressure and prone positioning: A proposal for an early management of COVID-19 patients

2020

In late December 2019, clusters of patients with interstitial pneumonia of unknown cause were reported by some local health facilities in Wuhan (China). The Chinese Centre for Disease Control conducted an epidemiologic and etiologic investigation, leading to the identification of a novel coronavirus (SARS-CoV-2).1, 2 On March 11th, the World Health Organization (WHO) declared the novel coronavirus disease (COVID-19) a pandemic. In the area of Wuhan, COVID-19 mainly affected male patients (around 60%), with a median age of about 50 years; 40% of patients developed Acute Respiratory Distress Syndrome (ARDS) 5% requiring intensive care. The mortality rate was around 2%.3, 4 However, Grasselli …

Pulmonary and Respiratory Medicine2019-20 coronavirus outbreakmedicine.medical_specialtyCoronavirus disease 2019 (COVID-19)medicine.medical_treatmentSevere acute respiratory syndrome coronavirus 2 (SARS-CoV-2)Pneumonia ViralcoronavirusArticlePatient PositioningPositive-Pressure RespirationBetacoronavirusPandemicmedicineHumansContinuous positive airway pressurePositive-Pressure RespirationHypoxiaLung CompliancePandemicslcsh:RC705-779Respiratory Distress SyndromeContinuous Positive Airway PressurebiologySARS-CoV-2business.industryhelmetCOVID-19lcsh:Diseases of the respiratory systembiology.organism_classificationProne positionVasoconstrictionprone positionEmergency medicineHead Protective DevicesCoronavirus InfectionsRespiratory InsufficiencybusinessBetacoronavirusCPCP COVID-19 SARS-CoV-2
researchProduct

Sociodemographic factors associated with time to discharge for hospitalised patients with asthma and asthma exacerbation using the Ghana Health Servi…

2021

ObjectiveData on asthma hospitalisations are a useful source of patient morbidity information. In Ghana, the length of stay (LoS) and sociodemographic factors of patients hospitalised for asthma and its exacerbation are understudied. We aimed to investigate the time to discharge and assessed factors associated with length of hospital stays of asthmatics in Ghana.MethodsRetrospective analysis of hospitalised patient with asthma records between 2012 and 2017 from the nationwide Ghana Health Service District Health Information Management System 2 database. We calculated the cumulative incidence function for discharge stratified by age group and sex. Multivariable Cox regression was used to inv…

Pulmonary and Respiratory MedicineAdultSociodemographic FactorsExacerbationInformation Managementcomputer.software_genreGhanaHealth servicesDiseases of the respiratory systemHealth caremedicineHumans1506ChildEarly dischargeAsthmaRetrospective StudiesAsthma exacerbationsDatabaseRC705-779business.industryProportional hazards modelasthma epidemiologyRmedicine.diseaseComorbidityAsthmaPatient DischargeCOPD exacerbationsMedicineFemalebusinesscomputerBMJ Open Respiratory Research
researchProduct

Coil embolisation for massive haemoptysis in cystic fibrosis.

2021

IntroductionMassive haemoptysis is a life-threatening event in advanced cystic fibrosis (CF) lung disease with bronchial artery embolisation (BAE) as standard of care treatment. The aim of our study was to scrutinise short-term and long-term outcomes of patients with CF and haemoptysis after BAE using coils.MethodsWe carried out a retrospective cohort study of 34 adult patients treated for massive haemoptysis with super selective bronchial artery coil embolisation (ssBACE) between January 2008 and February 2015. Embolisation protocol was restricted to the culprit vessel(s) and three lobes maximum. Demographic data, functional end-expiratory volume in 1 s in % predicted (FEV1% pred.) and bod…

Pulmonary and Respiratory MedicineAdultmassive haemoptysismedicine.medical_specialtyHemoptysisCystic FibrosisMedizinBronchial ArteriesCulpritCystic fibrosisDiseases of the respiratory systemmedicine.arterymedicineHumansIn patient22181506Coil embolizationRetrospective StudiesRC705-779business.industryRRetrospective cohort studymedicine.diseaseEmbolization TherapeuticSurgeryMedicineSputummedicine.symptomBronchial arterybusinessBody mass indexBMJ open respiratory research
researchProduct

The role of mucin 1 in respiratory diseases

2020

Recent evidence has demonstrated that mucin 1 (MUC1) is involved in many pathological processes that occur in the lung. MUC1 is a transmembrane protein mainly expressed by epithelial and hematopoietic cells. It has a receptor-like structure, which can sense the external environment and activate intracellular signal transduction pathways through its cytoplasmic domain. The extracellular domain of MUC1 can be released to the external environment, thus acting as a decoy barrier to mucosal pathogens, as well as serving as a serum biomarker for the diagnosis and prognosis of several respiratory diseases such as lung cancer and interstitial lung diseases. Furthermore, bioactivated MUC1-cytoplasmi…

Pulmonary and Respiratory MedicineAnti-Inflammatory Agents03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicinePulmonary fibrosismedicineAnimalsHumansRespiratory systemLung cancerMUC1lcsh:RC705-779Lungbusiness.industryMucinMucin-1lcsh:Diseases of the respiratory systemmedicine.diseaseAsthmaIntracellular signal transductionBiomarkermedicine.anatomical_structure030228 respiratory system030220 oncology & carcinogenesisCancer researchbusinessSignal Transduction
researchProduct

Is the patient's baseline inhaled steroid dose a factor for choosing the budesonide/formoterol maintenance and reliever therapy regimen?

2011

Objective: Baseline inhaled corticosteroid (ICS) dose may be a factor for prescribers to consider when they select a budesonide/formoterol maintenance and reliever therapy regimen for symptomatic asthmatics. Methods: A 6-month randomized study compared two maintenance doses of budesonide/formoterol 160/4.5 µg, 1 × 2 and 2 × 2, plus as needed, in 8424 asthma patients with symptoms when treated with ICS ± an inhaled long-acting β2-agonist (LABA). In the total study population, 1339 (17%) were high-dose ICS (HD) users (≥1600 µg/day budesonide). This HD stratum was compared with the rest of the study population, divided into low-dose (LD; 400 µg/day) and medium-dose strata (MD; 401–1599 µg/day…

Pulmonary and Respiratory MedicineBudesonideAdultMalemedicine.medical_specialtyTime FactorsAdolescentmedicine.drug_classSeverity of Illness Indexlaw.inventionYoung AdultRandomized controlled triallawAdrenal Cortex HormonesInternal medicineSurveys and QuestionnairesAdministration InhalationmedicineBudesonide Formoterol Fumarate Drug CombinationHumansPharmacology (medical)Anti-Asthmatic AgentsBudesonideAsthmaAgedlcsh:RC705-779Aged 80 and overDose-Response Relationship Drugbusiness.industrylcsh:Diseases of the respiratory systemMiddle Agedmedicine.diseaseAsthmaRegimenDrug CombinationsTreatment OutcomeBudesonide/formoterolAsthma Control QuestionnaireEthanolaminesAnesthesiaCorticosteroidFemaleFormoterolbusinessmedicine.drugTherapeutic advances in respiratory disease
researchProduct

The effect of budesonide/formoterol maintenance and reliever therapy on the risk of severe asthma exacerbations following episodes of high reliever u…

2012

Abstract Background Divergent strategies have emerged for the management of severe asthma. One strategy utilises high and fixed doses of maintenance treatment, usually inhaled corticosteroid/long-acting β2-agonist (ICS/LABA), supplemented by a short-acting β2-agonist (SABA) as needed. Alternatively, budesonide/formoterol is used as both maintenance and reliever therapy. The latter is superior to fixed-dose treatment in reducing severe exacerbations while achieving similar or better asthma control in other regards. Exacerbations may be reduced by the use of budesonide/formoterol as reliever medication during periods of unstable asthma. We examined the risk of a severe exacerbation in the per…

Pulmonary and Respiratory MedicineBudesonideExacerbationAsthma in primary careSeverity of Illness Indexlaw.inventionRandomized controlled trialDouble-Blind MethodlawAdrenal Cortex HormonesRisk FactorsFormoterol FumarateAdministration InhalationmedicineBudesonide Formoterol Fumarate Drug CombinationHumansAnti-Asthmatic AgentsBudesonideAsthmalcsh:RC705-779Maintenance dosebusiness.industryResearchlcsh:Diseases of the respiratory systemmedicine.diseaseAsthmaBronchodilator AgentsDrug CombinationsTreatment OutcomeBudesonide/formoterolEthanolaminesAnesthesiaDisease ProgressionFormoterol FumarateDrug Therapy CombinationFormoterolbusinesshormones hormone substitutes and hormone antagonistsmedicine.drugRespiratory research
researchProduct

Cigarette smoke exposure inhibits extracellular MMP-2 (gelatinase A) activity in human lung fibroblasts

2007

Abstract Background Exposure to cigarette smoke is considered a major risk factor for the development of lung diseases, since its causative role has been assessed in the induction and maintenance of an inflamed state in the airways. Lung fibroblasts can contribute to these processes, due to their ability to produce proinflammatory chemotactic molecules and extracellular matrix remodelling proteinases. Among proteolytic enzymes, gelatinases A and B have been studied for their role in tissue breakdown and mobilisation of matrix-derived signalling molecules. Multiple reports linked gelatinase deregulation and overexpression to the development of inflammatory chronic lung diseases such as COPD.…

Pulmonary and Respiratory MedicineGelatinase ABiologyMatrix metalloproteinaseProinflammatory cytokineExtracellular matrixExtracellularHumansGelatinaseRNA MessengerLungCells Culturedlcsh:RC705-779Cell DeathPlant ExtractsResearchProteolytic enzymessmoke MMP-2Tissue Inhibitor of MetalloproteinasesEnvironmental Exposurelcsh:Diseases of the respiratory systemEnvironmental exposureFibroblastsrespiratory systemrespiratory tract diseasesCulture Media ConditionedImmunologyMatrix Metalloproteinase 2Tobacco Smoke PollutionEnvironmental MonitoringRespiratory Research
researchProduct

Obstructive sleep apnoea in acute coronary syndrome.

2019

Obstructive sleep apnoea (OSA) syndrome affects about 13% of the male and 7–9% of the female population. Hypoxia, oxidative stress and systemic inflammation link OSA and cardiovascular and metabolic consequences, including coronary artery disease. Current research has identified several clinical phenotypes, and the combination of breathing disturbances during sleep, systemic effects and end-organ damage might help to develop personalised therapeutic approaches. It is unclear whether OSA is a risk factor for acute coronary syndrome (ACS) and might affect its outcome. On the one hand, OSA in patients with ACS may worsen prognosis; on the other hand, OSA-related hypoxaemia could favour the dev…

Pulmonary and Respiratory MedicineMaleAcute coronary syndromemedicine.medical_specialtymedicine.medical_treatmentSettore MED/10 - Malattie Dell'Apparato Respiratorio030204 cardiovascular system & hematologySystemic inflammationCoronary artery disease03 medical and health sciences0302 clinical medicineRisk FactorsInternal medicinePositive airway pressurePrevalenceMedicineHumansContinuous positive airway pressureNon disponibiliAcute Coronary SyndromeAdverse effectLunglcsh:RC705-779Sleep Apnea ObstructiveContinuous Positive Airway Pressurebusiness.industryRespirationHemodynamicsSleep apnealcsh:Diseases of the respiratory systemHypoxia (medical)medicine.diseasenervous system diseasesrespiratory tract diseasesTreatment Outcome030228 respiratory systemCardiologyPatient ComplianceFemalemedicine.symptombusinessSleepEuropean respiratory review : an official journal of the European Respiratory Society
researchProduct

Satisfaction with chronic obstructive pulmonary disease treatment: results from a multicenter, observational study

2019

Background: Understanding the level of patients’ satisfaction with treatment and its determinants have the potential to impact therapeutic management and clinical outcome in chronic conditions such as chronic obstructive pulmonary disease (COPD). Methods: A national, multicenter, longitudinal, observational study of COPD from 20 Italian pulmonary centers to explore patients’ satisfaction to treatment [assessed by the Treatment Satisfaction Questionnaire, 9 items (TSQM-9)] and association with clinical parameters [including dyspnea score, COPD Assessment Test (CAT) score, exacerbation rate], adherence to treatment [Morisky Medication-Taking Adherence Scale (MMAS-4)], illness perception [eval…

Pulmonary and Respiratory MedicineMaleChronic Obstructivemedicine.medical_specialtyCOPD; adherence; treatment satisfactionPulmonary diseaseSocio-culturaleTreatment resultstreatment satisfactionSettore MED/10 - Malattie Dell'Apparato RespiratorioOutcome (game theory)Medication AdherencePulmonary Disease03 medical and health sciencesPulmonary Disease Chronic Obstructive0302 clinical medicineSurveys and QuestionnairesAdministration InhalationSettore MED/10MedicineHumansCOPDPharmacology (medical)030212 general & internal medicineadherenceIntensive care medicineOriginal ResearchAgedlcsh:RC705-779adherence COPD treatment satisfactionbusiness.industrylcsh:Diseases of the respiratory systemMiddle AgedDyspneaInhalation030228 respiratory systemItalyPatient SatisfactionAdministrationObservational studyFemalebusinessFollow-Up Studies
researchProduct

Preliminary development of a questionnaire to measure the extra-pulmonary symptoms of severe asthma

2021

Abstract Background Research into the effects of asthma treatments on the extra-pulmonary symptoms of severe asthma is limited by the absence of a suitable questionnaire. The aim was to create a questionnaire suitable for intervention studies by selecting symptoms that are statistically associated with asthma pathology and therefore may improve when pathology is reduced. Methods Patients attending a specialist asthma clinic completed the 65-item General Symptom Questionnaire (GSQ-65), a questionnaire validated for assessing symptoms of people with multiple medically unexplained symptoms. Lung function (FEV1%) and cumulative oral corticosteroids (OCS) calculated from maintenance dose plus ex…

Pulmonary and Respiratory MedicineMalemedicine.medical_specialtyFibromyalgiaSevere asthmaExtra pulmonaryDiseases of the respiratory systemFibromyalgiaInternal medicineAsthma controlForced Expiratory VolumeSurveys and QuestionnairesmedicineHealth Status IndicatorsHumansAsthma Symptoms Fibromyalgia Questionnaire Patient reported outcomesPatient reported outcomesLung functionAsthmaAgedAged 80 and overRC705-779business.industryMaintenance doseQuestionnaireextra-pulmonary symptomsAsthma clinicMiddle Agedmedicine.diseasesparse regressionAsthmarespiratory tract diseasesSymptomslinear regressionFemaleSymptom AssessmentbusinessResearch Article
researchProduct